Tetrameric Peptide Ligand for Plectin-1 Detection in Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for pancreatic cancer (PDAC) lack specificity and sensitivity, particularly for early detection and differentiation from chronic pancreatitis, and existing biomarkers are inadequate for non-invasive imaging and staging.
Innovation Solution
A tetrameric peptide ligand complex targeting Plectin-1, comprising peptides with specific amino acid sequences, optionally modified with non-standard amino acids and polyethylene glycol, coupled with chelating agents and imaging agents for non-invasive imaging and detection of PDAC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CA 19.9 is used as a serum biomarker for PDAC, then detection capability is provided, but specificity and sensitivity are insufficient especially for early detection and differentiation from chronic pancreatitis
Solution Approach 1:
The patent extracts and isolates a specific peptide sequence (KTLLPTP) that binds selectively to Plectin-1, separating the detection function from the non-specific CA 19.9 biomarker. This extracted peptide serves as a targeted ligand that specifically recognizes Plectin-1 expressed in PDAC cells, thereby improving both sensitivity and specificity for early detection while differentiating from chronic pancreatitis.
Solution Approach 2:
The patent changes the detection parameter from using a protein-based biomarker (CA 19.9) to using a peptide-based ligand (KTLLPTP) with specific amino acid sequence. This parameter change enables more precise binding to Plectin-1, enhancing measurement precision and reliability for detecting PDAC at early stages and distinguishing it from chronic pancreatitis.
2Measurement precision
If invasive endoscopic procedures (EUS and ERCP) are used to detect early lesions, then detection capability is improved, but potential for injury to the pancreas and high false negative rates occur
Solution Approach 1:
The patent introduces a peptide ligand (KTLLPTP) as an intermediary that binds to Plectin-1 on PDAC cell surfaces. This intermediary enables non-invasive detection through imaging techniques, eliminating the need for invasive endoscopic procedures while maintaining high detection precision. The peptide acts as a safe mediator that targets cancer cells without causing pancreatic injury or false negatives.
Solution Approach 2:
The patent replaces the mechanical invasive approach of endoscopic procedures with a molecular-level detection system using peptide ligands. Instead of physically inserting instruments into the pancreas, the system uses biochemical binding between the KTLLPTP peptide and Plectin-1, enabling detection through non-invasive imaging modalities and eliminating mechanical injury risks.
3Ease of operation
If cross-sectional abdominal imaging is used for early stage PDAC detection, then non-invasive detection is provided, but reliability fails to detect metastases and differentiate between chronic pancreatitis and PDAC
Solution Approach 1:
The patent creates a universal detection system where the KTLLPTP peptide ligand can be used across multiple imaging modalities and clinical scenarios. The peptide maintains consistent specific binding to Plectin-1 regardless of the imaging technique used, enabling reliable detection of primary tumors, metastases, and differentiation from chronic pancreatitis all through non-invasive approaches.
Solution Approach 2:
The patent employs a composite detection approach combining the peptide ligand (KTLLPTP) with various imaging agents and modalities. This composite system integrates the specific biochemical recognition capability of the peptide with the non-invasive imaging advantages, achieving both ease of operation and high reliability for detecting metastases and differentiating PDAC from chronic pancreatitis.
4Measurement precision
If no specific biomarker is available for early PDAC detection, then current diagnostic tools cannot distinguish malignant from benign or premalignant lesions, but developing such biomarkers requires identifying specific molecular targets
Solution Approach 1:
The patent performs preliminary identification of Plectin-1 as a specific molecular target expressed in PDAC before developing the detection system. By pre-establishing the target and its corresponding peptide ligand (KTLLPTP), the patent simplifies the overall diagnostic approach and enables precise lesion characterization without requiring complex real-time molecular analysis during clinical procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tetrameric peptide ligand complex provides sensitive and specific detection of Plectin-1, enabling early detection and staging of PDAC, improving diagnostic accuracy and potentially leading to earlier treatment and improved survival rates.
Implementation Method 1
A tetrameric peptide ligand complex targeting Plectin-1, comprising peptides with specific amino acid sequences
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (βAKTLLPTPGGS(PEG5000))4 KKKKDOTAβA-NH2, to which imaging agents and/or therapeutic agents can be conjugated.